MSF Scientific Days

9-10 May 2019
London, UK

  • Fabiana Barreira, Chagas Senior Clinical Manager – presentation of the BENDITA trial for Chagas disease
  • Nathalie Strub-Wourgaft, Director NTDs – presentation on registration steps for the new all oral sleeping sickness treatment

Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo

Paris/Geneva – 30 January 2019
Marketing authorization of fexinidazole for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis, more commonly known as sleeping sickness, has been granted in the Democratic Republic of Congo (DRC). This approval paves the way for the distribution of fexinidazole in endemic countries this year, with another submission planned in Uganda.

DNDi North America submits brief to the Canadian Standing Committee on Health (HESA) Study on Federally Funded Health Research

October 2018
To help inform the Canadian government’s approach to biomedical innovation, particularly as relates to innovations of public health importance, DNDi has submitted a contribution providing concrete evidence of DNDi’s experience implementing needs-driven, open, collaborative R&D. The contribution recommends a series of progressive policy steps Canada can support to re-orient the global biomedical R&D system so that it (1) prioritizes patient and public health needs; (2) is sustainably financed; and (3) incorporates global norms that will enable the discovery, development, and delivery of and equitable access to innovations of public health importance.